Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant and Olanzapine for CINV in Autologous SCT
NCT02939287Phase 3Completed
- Sponsor
- Rush University Medical Center
- Start
- Sep 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aprepitant and olanzapine in nausea ((none)) and Vomiting (3 arms), sponsored by Rush University Medical Center. Primary endpoint: Complete Response at 120 hours. Started Sep 2017; status: completed.
02
Drugs
aprepitantolanzapine
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on NCT02939287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939287.